Figure 6: Analysis of circulating CD147 and CD9 double-positive EVs in healthy donors or colorectal cancer patient sera.

(a) Serum levels of CD147/CD9 double-positive EVs in colorectal cancer patients without any purification. The panel shows a scatter plot for healthy donors (n=191) and colorectal cancer patients (n=194). The P-value was calculated by using Wilcoxon rank-sum test. (b) Changes in serum levels of CD147/CD9 double-positive EVs in colorectal cancer patients (stage I or II: n=15) before (preoperation) and after (postoperation after 7–34 days) surgical removal of the tumor. Box lengths represent the interquartile range (first to third quartiles). The line in the center of the boxes represents the median value. Data represented by the asterisks are extreme values (greater than three times the interquartile range over the third quartile). The P-value was calculated by using Wilcoxon signed-rank test. (c) The results of ExoScreen detection of circulating EVs (left panel) and purified circulating EVs (right panel) in sera from healthy donors (n=10) and colorectal cancer patients (n=35) using CD147 and CD9 antibodies. The panels show the signal intensities from each samples measured for CD147/CD9 double-positive EVs using ExoScreen. (d) Receiver operating characteristic curves between healthy donors and colorectal cancer patients assesing by CD147/CD9 double-positive EVs (left panel), CEA and CA19-9 (right panel). left panel, CD147/CD9 double-positive EVs (healthy donors versus colorectal cancer patients; AUC: 0.820); right panel, CEA (AUC: 0.669); CA19-9 (AUC: 0.622) Data are representative of at least three independent experiments each. AUC, area under the curve.